Gemtuzumab ozogamicin for relapsed APL with maintenance

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-GEMTUZUMAB-OZOGAMICIN` `DRUG-ATRA` `DRUG-ATO`

ID	`REG-GEMTUZUMAB-APL`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-APL-RELAPSE-LENGFELDER-2017` `SRC-MYLOFRANCE-ARIBI-2007` `SRC-NCCN-AML-2025`

Notes

Gemtuzumab combined with ATRA + ATO for relapsed APL — APL is exquisitely CD33+, rapid deep MRD-negative responses common (CR ~91% per MyloFrance). Maintenance with gemtuzumab during consolidation cycles. Bridge to autoSCT for fit molecularly-CR responders. STUB — pending Co-Lead sign-off.

Used By

Indication

IND-APL-RELAPSED-GEMTUZUMAB - IND-APL-RELAPSED-GEMTUZUMAB